Table 1 Baseline characteristics of the mITT cohorts

From: Durability of single-dose HPV vaccination in young Kenyan women: randomized controlled trial 3-year results

 

HPV 16/18 mITT

HPV 16/18/31/33/45/52/58 mITT

 

Nonavalent HPV

Bivalent HPV

Control

Nonavalent HPV

Control

Characteristic

Category

  
 

Total

496

489

473

325

290

Age group (years)

15–17

299 (60.3%)

278 (56.9%)

278 (58.8%)

197 (60.6%)

168 (57.9%)

 

18–20

197 (39.7%)

211 (43.1%)

195 (41.2%)

128 (39.4%)

122 (42.1%)

Age (years)

Median (IQR)

17 (16, 18)

17 (16, 19)

17 (16, 19)

17 (16, 18)

17 (16, 19)

Marital status

Never married

478 (96.4%)

462 (94.5%)

446 (94.3%)

315 (96.9%)

269 (92.8%)

 

Married

14 (2.8%)

24 (4.9%)

20 (4.2%)

7 (2.2%)

15 (5.2%)

 

Previously married

3 (0.6%)

3 (0.6%)

7 (1.5%)

2 (0.6%)

6 (2.1%)

 

Other

1 (0.2%)

0 (0.0%)

0 (0.0%)

1 (0.3%)

0 (0.0%)

Education (highest level)

No schooling

1 (0.2%)

2 (0.4%)

1 (0.2%)

1 (0.3%)

1 (0.3%)

 

Primary school, some or complete

40 (8.1%)

30 (6.1%)

36 (7.6%)

27 (8.3%)

27 (9.3%)

 

Secondary school, some or complete

359 (72.4%)

368 (75.3%)

355 (75.1%)

241 (74.2%)

220 (75.9%)

 

Post-secondary school

96 (19.4%)

89 (18.2%)

81 (17.1%)

56 (17.2%)

42 (14.5%)

Earns an income of her own

No

437 (88.1%)

417 (85.3%)

417 (88.2%)

284 (87.4%)

248 (85.5%)

 

Yes

59 (11.9%)

72 (14.7%)

56 (11.8%)

41 (12.6%)

42 (14.5%)

Has a current main or steady sexual partner

No

144 (29.0%)

152 (31.1%)

145 (30.7%)

98 (30.2%)

95 (32.8%)

 

Yes

352 (71.0%)

337 (68.9%)

328 (69.3%)

227 (69.8%)

195 (67.2%)

Age when first had vaginal intercourse (years)

<15

123 (24.8%)

116 (23.7%)

103 (21.8%)

80 (24.6%)

65 (22.4%)

 

15–17

265 (53.4%)

274 (56.0%)

282 (59.6%)

185 (56.9%)

173 (59.7%)

 

≥18

96 (19.4%)

93 (19.0%)

79 (16.7%)

54 (16.6%)

46 (15.9%)

 

Do not remember

12 (2.4%)

6 (1.2%)

9 (1.9%)

6 (1.8%)

6 (2.1%)

Lifetime number of sex partners

1

322 (64.9%)

332 (67.9%)

289 (61.1%)

217 (66.8%)

184 (63.4%)

 

2

121 (24.4%)

100 (20.4%)

113 (23.9%)

78 (24.0%)

65 (22.4%)

 

≥3

53 (10.7%)

57 (11.7%)

71 (15.0%)

30 (9.2%)

41 (14.1%)

Condom use with last vaginal sex

No

153 (30.8%)

155 (31.7%)

140 (29.6%)

98 (30.2%)

78 (26.9%)

 

Yes

237 (47.8%)

235 (48.1%)

238 (50.3%)

156 (48.0%)

144 (49.7%)

 

No sex in past year

106 (21.4%)

99 (20.2%)

95 (20.1%)

71 (21.8%)

68 (23.4%)

Syphilis

Negative

496 (100.0%)

489 (100.0%)

471 (99.6%)

325 (100.0%)

289 (99.7%)

 

Positive

0

0

1 (0.2%)

0

1 (0.3%)

 

Not done

0

0

1 (0.2%)

0

0

Chlamydiatrachomatis

Negative

438 (88.3%)

434 (88.8%)

413 (87.3%)

293 (90.2%)

252 (86.9%)

 

Positive

58 (11.7%)

55 (11.2%)

60 (12.7%)

32 (9.8%)

38 (13.1%)

Neisseriagonorrhoeae

Negative

488 (98.4%)

480 (98.2%)

466 (98.5%)

322 (99.1%)

285 (98.3%)

 

Positive

8 (1.6%)

9 (1.8%)

7 (1.5%)

3 (0.9%)

5 (1.7%)

HSV-2

Negative

407 (82.1%)

387 (79.1%)

375 (79.3%)

264 (81.2%)

226 (77.9%)

 

Positive

88 (17.7%)

102 (20.9%)

98 (20.7%)

60 (18.5%)

64 (22.1%)

 

Indeterminate

1 (0.2%)

0

0

1 (0.3%)

0

BVa

Negative

415 (83.7%)

378 (77.3%)

378 (79.9%)

278 (85.5%)

239 (82.4%)

 

Positive

81 (16.3%)

111 (22.7%)

95 (20.1%)

47 (14.5%)

51 (17.6%)

Trichomonasvaginalis

Negative

477 (96.2%)

468 (95.7%)

452 (95.6%)

315 (96.9%)

275 (94.8%)

 

Positive

19 (3.8%)

21 (4.3%)

21 (4.4%)

10 (3.1%)

15 (5.2%)

  1. aNugent scores 7–10 were classified as BV positive and Nugent scores 0–6 were classified as BV negative. BV, bacterial vaginosis; IQR, interquartile range; HSV, herpes simplex virus.